Authors
Delita Prihatni, Nur Izzatun Nafsi, Ernawati Ernawati, Nina Susana Dewi, Almira Zada, Yunia Sribudiani
Published in
Cancer management and research. Volume 18. Pages 607952. Epub Sep 29, 2026.
Abstract
There are limited commercial kits available for the identification of BCR-ABL1 gene fusion transcripts in chronic myeloid leukaemia (CML) patients. Most kits are based on RT-PCR to detect e14a2 and e13a2 transcripts as major breakpoint segments, but do not detect minor transcripts. Therefore, this study aimed to develop a multiplex PCR approach for BCR-ABL gene transcripts.
Primers were designed to amplify four BCR-ABL1 transcripts from the cDNA reverse transcribed from 52 archived mRNAs from CML patients. The BCR-ABL1 transcripts were identified by multiplex PCR, and the assay performance was compared to Xpert® BCR-ABL Ultra (GeneXpert).
The multiplex TD-PCR successfully amplified four BCR-ABL1 transcripts, with detection limits of 10 fg/µL for e13a2 and e14a2 and 100 fg/µL for e1a2 and e19a2. Out of 52 archived RNA samples, 40 were confirmed positive. The most common transcript was e14a2, which was identified in 72.5% of the confirmed positive samples, followed by e13a2, identified in 25% of the positive samples. The e19a2 transcript was identified in 2.5% of the positive samples. No patients expressed the e1a2 transcript type or co-expressed both e14a2 and e13a2. The overall sensitivity and specificity of the multiplex PCR when compared to GeneXpert results were 97.56% (95% CI: 87.14-99.94%) and 100% (95% CI: 71.51-100%), respectively.
The multiplex PCR assay developed to identify the four BCR-ABL1 transcripts can be implemented in CML diagnostic settings.
PMID:
42829610
Bibliographic data and abstract were imported from PubMed on 04 Oct 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 7
- Comments 0